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Toll-Like Receptor-4 Disruption 
Suppresses Adipose Tissue 
Remodeling and Increases Survival 
in Cancer Cachexia Syndrome
Felipe Henriques1,2, Magno A. Lopes1, Felipe O. Franco1, Pamela Knobl1, 
Kaltinaitis B. Santos1, Luana L. Bueno1, Victor A. Correa1, Alexander H. Bedard  2, 
Adilson Guilherme2, Alexander Birbrair3, Sidney B. Peres4, Stephen R. Farmer5 & 
Miguel L. Batista Jr.  1
Cancer-induced cachexia, characterized by systemic inflammation, body weight loss, adipose tissue 
(AT) remodeling and muscle wasting, is a malignant metabolic syndrome with undefined etiology. Here, 
we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the 
main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). AT remodelling was not 
found in LLC tumor-bearing (TB) TLR4−/− mice due to reduced macrophage infiltration and adipocyte 
atrophy. TLR4−/− mice were also resistant to cold-induced browning of subcutaneous AT (scAT). 
Importantly, pharmacological inhibition of TLR4 (Atorvastatin) reproduced the main protective effect 
against AT remodeling found in TLR4−/− TB mice. Moreover, the treatment was effective in prolonging 
survival and attenuating tumor mass growth when compared to non-treated-TB animals. Furthermore, 
tumor-induced elevation of circulating pro-inflammatory cytokines was similarly abolished in both 
genetic ablation and pharmacological inhibition of TLR4. These data suggest that TLR4 is a critical 
mediator and a promising target for novel anti-cachexia therapies.
Cancer cachexia syndrome is characterized by systemic inflammation, body weight loss, remodeling of adipose 
tissue (AT), and skeletal muscle wasting1. Consequently, it results in reduced quality of life, decreased survival, 
and increased complications due to cancer treatment. Cachexia is the main cause of death in approximately 20% 
to 30% of all patients with cancer2. In cancer cachexia patients, impairment of AT lipid metabolism has been 
demonstrated and longitudinal studies have established that AT loss precedes muscular atrophy3. The changes 
that characterize AT remodeling comprise: an increase in infiltrated inflammatory cells4,5, extracellular matrix 
rearrangement4,6 and the appearance of beige cells7 in subcutaneous AT (scAT). The physiological role and conse-
quences of cachexia-induced browning are not known. The current consensus is that multiple factors contribute 
to cancer cachexia, and therapy requires combinational strategies8. Interestingly, pharmacological intervention 
aimed at attenuating the AT remodeling in cachexia have shown satisfactory results, particularly in mitigating 
tumor growth and increasing animal survival9.
A plethora of evidence from both patients and animal studies suggest a compelling link between activation 
of the inflammatory pathways and development of cancer cachexia10,11. In fact, systemic inflammation has been 
proposed as a critical feature of cancer cachexia, and anti-inflammatory strategies are considered central to the 
therapy10. It is likely that pathways responding to similar pro-inflammatory cytokines that mediate both sterile 
and infectious inflammation are critical in cancer cachexia. The toll-like receptor (TLR) system is potentially one 
such pathway. TLRs are required for pathogen recognition by the innate immune system12. Among TLRs, TLR4 
acts as a receptor for lipopolysaccharides (LPS), and associates with the myeloid differentiation protein 2 (MD2) 
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to form a complex to interact with LPS13. The stimulation of TLR4 by LPS induces the release of critical proin-
flammatory cytokines that are necessary to activate potent immune responses12,13.
In a cancer cachexia animal model, genetic ablation of TLR4 elicited a less severe cachexia with an accompa-
nying lower body weight loss, greater lean body and fat mass, and clinical evidence of reduced wasting compared 
with the age and weight-matched WT mice11. More recently, an elegant study showed that TLR4 is a crucial 
mediator of cancer-induced muscle wasting due to its integration of catabolic signaling by directly activating 
muscle protein degradation and indirectly increasing cytokine release10. Thus, TLR4 may be a critical therapeutic 
target for cancer cachexia. The role of the TLR4 pathway in AT remodeling during cancer cachexia development 
remains unexplored.
Based on these considerations, the present study was designed to further investigate the role of TLR4 on 
AT remodeling and cachexia development. Using a genetic ablation and pharmacological inhibition of 
TLR4 we demonstrate that the TLR4 pathway plays an essential role in modulating both thermogenic and 
pro-inflammatory pathways in fat. Suppression of TLR4 signaling results in a robust resistance to AT remodeling, 
reduced cachexia, and increased survival. Our study sheds light on TLR4 pathway as a promising target for ther-
apeutic intervention for cachexia.
Results
TLR4 deletion attenuates AT remodeling induced by cancer cachexia in TB-mice. During the 
development of cancer cachexia, AT remodeling arises from morphofunctional and inflammatory changes that 
result in AT dysfunction. Consistent with these observations, we used the Lewis Lung Carcinoma (LLC) cell line 
to induce cancer-associated cachexia in vivo10,11. Additionally, we also determined whether LLC tumor induces 
AT remodeling through activation of TLR4-mediated AT immunometabolism changes. Thus, we utilized the 
existing TLR4−/− mice14 to examine the role of TLR4 in cancer cachexia. 28 days after LLC cell inoculation a 12% 
reduction in body weight was measured in tumor-bearing wild-type (WT TB) mice, a classic sign of cachexia 
(Fig. 1A). However, in the TLR4−/− TB mice there was no weight loss, without any differences in tumor growth 
(Fig. S1). No pulmonary metastasis was detected in any of the evaluated TB groups.
Adipocyte atrophy in scAT, demonstrated by a marked reduction in adipocyte size (58.2%), and signifi-
cantly increased fibrosis, demonstrated by total collagen content in the extracellular matrix (Fig. 1B,C), were 
also observed in WT TB mice. Furthermore, the presence of CD68 and TNF-α positive staining in scAT was 
found, while no significant difference in CD3 positive cells in scAT was observed (Fig. 1B). On the other hand, 
tumor-bearing TLR4−/− TB mice presented less adipocyte atrophy and a reduction in the number of TNF-α and 
CD-68 positive cells in scAT when compared to WT TB group (Fig. 1A–C). Taken together, the effects of cachexia 
on inducing AT remodeling were attenuated in TLR4−/− TB mice.
To better understand AT inflammation and the role of macrophage polarization during cancer-associated 
cachexia, we evaluated AT macrophage (ATMφs) profiles in scAT from WT and TLR4−/− mice during develop-
ment of the cachexia syndrome. In this case, scAT demonstrated an increase in ATMφs (6.0-fold) (Fig. 1D,E) with 
an enhancement in M1 (7.0-fold) and a decrease in M2 ATMφs in the WT TB mice (Fig. 1D). In contrast, the 
TLR4−/− TB mice presented a consistent attenuation in ATMφs infiltration (55.3%) and a decrease in the ratio of 
M1/M2 macrophages (93.2%) in the scAT when compared to WT TB mice (Fig. 1D,E). In models of LLC-induced 
cachexia, ATMφs polarization tends to be directed towards an M1 phenotype, making these results even more 
significant. In addition to the macrophage polarization, the proportion of M2 macrophage was higher in the 
TLR4−/− (4.5-fold) and TLR4−/− TB (8-fold) mice when we compared with their respective controls (Fig. 1D). 
Therefore, the attenuation of TLR4 was associated with a reduction in the recruitment process of ATMφs, thus 
playing an interesting role in the development of cancer cachexia syndrome.
Triglyceride turnover is not affected during cachexia in TLR4−/− TB-mice. Considering the atten-
uation of the AT remodeling seen in the TLR4−/− TB mice in response to cachexia, the next step was to evaluate 
the cachectic response of primary adipocytes (scAT) after isoproterenol (ISO)-stimulus, to evaluate the lipolytic 
response. During the development of cachexia, an increase in glycerol release (1.2- fold) was observed in the WT 
TB group compared to the WT group (Fig. 2A). On the contrary, adipocytes in the TLR4−/− TB mice showed 
lower lipolytic response when compared to the WT TB group (Fig. 2A).
Once the attenuation of cachexia-induced lipolysis was shown in the TLR4−/− TB mice, serum concentrations 
of non-esterified fatty acids (NEFA) and palmitic acid levels from the scAT in the different experimental groups 
were evaluated (Fig. 2B,C). A significant increase was found in NEFA serum concentrations after the cachexia 
induction in WT TB mice. However, the serum concentration of NEFA was reduced by 36.3% in the TLR4−/− TB 
mice (Fig. 2B) when compared to the WT TB mice. Palmitic acid levels in scAT were reduced by 18.9% in the 
WT TB mice when compared with the WT mice (Fig. 2C). Interestingly, the TLR4−/− group had lower levels of 
palmitic acid in the scAT when compared to the WT group and no difference was observed between the TLR4−/− 
and TLR4−/− TB mice (Fig. 2C).
The main lipolytic enzymes were also evaluated. Hormone-sensitive lipase (HSL) showed an increased phos-
phorylation at ser-660 in the WT TB group, without any alteration in the TLR4−/− TB group (Fig. 2D,E). In this 
scenario, since triglyceride (TG) turnover is affected by cachexia and partially diminished by TLR4 deletion, we 
evaluated genes involved in fatty acid metabolism in adipocytes. In general, the effect of cachexia on the expres-
sion of scAT metabolic markers was reduced in the absence of TLR4. In particular, cachexia reduced expression 
of Pck1, Acsl1, Acads and Me3 in the WT TB, but not in the TLR−/− TB mice (Fig. 2F).
TLR4 deletion reduces AT browning and p38MAPK signaling in TB mice. To assess whether TLR4 
mediates AT energy expenditure, thermogenic markers were measured in scAT. We found that UCP1 staining 
was increased (1.3-fold) in TB mice (Fig. 3A,B). Surprisingly, TLR4−/− and TLR4−/− TB mice showed a significant 
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Figure 1. TLR4 deletion attenuates scAT remodeling during cancer cachexia syndrome. (A) Wild-type 
C57BL/6 and TLR4−/− mice (8-week old male) were inoculated with LLC tumor cells. Body weight change 
(excluding tumor weight) was evaluated after 28 days before inoculated tumor cells. N = 10 per group. (B) 
Histologic sections of scAT in different experimental groups. Histological staining for H/E and picrosirius red 
were performed, and also, immunohistochemistry for inflammatory profile (TNFα) and immune cell markers 
(CD68 and CD3). N = 5 per group. (C) The size of adipocytes (cell diameter) from WT and TLR4−/− mice 
was quantitatively analyzed (500 adipocytes were measured for each group) after the experimental protocol. 
N = 5 per group. (D) Stromal vascular fractions (SVF) were isolated from scAT by collagenase digestion for 
each different group. Flow cytometric analysis of SVF was conducted using fluorescent-conjugated antibodies 
against CD68, F4/80, CD11c, CD206. Adipose tissue macrophages (ATMφs) were defined as CD68+F4/80+ 
subpopulations and displayed the values as percentage of your respective groups. M1 and M2 ATMφs were 
defined as CD68+F4/80+CD11c+CD206− and CD68+F4/80+CD11c−CD206+, respectively. Representative 
flow cytometric dot plots showing the percentage of ATMφs. N = 4 per group. (E) Quantification of double-
positive cells for CD68+F4/80+ related to dot plots showed in (D). (F) M1/M2 ATMφs ratio in the scAT. Scale 
bars, 100 μm and 200 μm. Graphs show the mean ± SEM. Statistical significance was determined by two-way 
ANOVA. **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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reduction in UCP1 staining (Fig. 3A,B). Corroborating this data, the gene profile of the browning “signature” 
from scAT showed a marked upregulation of Ucp1 levels in the WT TB mice, but in the TLR4−/− TB mice there 
was a significant attenuation in the browning profile, as illustrated in Fig. 3C.
Figure 2. Reduced triglyceride (TG) turnover is observed in TLR4−/− TB-mice. (A) Primary adipocytes from 
scAT were incubated in the presence (stimulated) or absence (basal) of isoproterenol (10−5M) for 1 hour. Graph 
shows lipolysis response assessed by the ratio of glycerol released (nmol/104 cells) relative to the basal condition. 
N = 4 per group. (B) Serum concentrations of non-esterified fatty acids (NEFA) and (C) % of palmitic acid 
in scAT were performed for each different group. N = 4 per group. (D) Immunoblot analysis for components 
of lipolysis. scAT lysates were immunoblotted for phospho-HSL (Ser660) and total HSL (E) Densitometric 
evaluation of phospho-HSL (Ser660) and total HSL. Ponceau staining was analyzed as a loading control. N = 4 
per group. (F) qRT-PCR was performed to quantitate Pck1, Acsl1, Acads, Citrate Synthase, Me3 and Cpt1b 
mRNA levels in scAT from the different groups. N = 5 per group. Graph show the mean ± SEM. Statistical 
significance was determined by two-way ANOVA. *P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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Adaptive thermogenesis and UCP1 expression are mainly regulated by sympathetic tone through β-adrenergic 
signaling and cAMP levels, which can be directly sensed by protein kinase A (PKA) and thus lead to direct or 
indirect activation of p38 MAPK. Although cachexia induced phosphorylation of p38 MAPK in the WT TB 
group, there was no change in the TLR4−/− TB group. (Fig. 3D,E). There were also no changes in phosphoryla-
tion of AMPK (Fig. 3D,E) and PKA substrates in any of the experimental conditions evaluated (Fig. S2) in the 
TLR4−/− TB mice.
Figure 3. TLR4 deletion reduces browning effect in TB mice throughout p38MAPK pathway. (A) 
Representative images of UCP1 staining of scAT from the different experimental groups. N = 5 per group. (B) 
Total quantification of UCP1 staining. (C) qRT-PCR was performed to quantitate Ucp1, Pgc1a, Prdm16, Cidea, 
Cidec, Adrb1 and Adrb3 mRNA levels in scAT from the different groups. N = 5 per group. (D) Depicted are 
representative immunoblots to detect phospho-p38MAPK, p38MAPK, phospho-AMPK and AMPK levels in 
scAT from the different experimental groups. N = 4 per group. (E) Densitometric evaluation of protein levels 
(phospho/total). Scale bars, 200 μm. Graphs show the mean ± SEM. Statistical significance was determined by 
two-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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TLR4 is required for cold-induced browning of inguinal white adipose tissue. Having shown that 
TLR4 is required for full browning of scAT during cancer-associated cachexia, we subjected WT and TLR4−/− 
mice to chronic cold (6 °C) challenge to see if TLR4 is required for general adaptive thermogenesis. There was 
a marked reduction in cold-induced browning in the TLR4−/− mice compared to the WT mice (Fig. 4A,B). 
Interestingly, expression of proteins linked to the lipolytic pathway (Phospho HSL and ATGL) were the same 
across both groups (WT 6 °C and TLR4−/− 6 °C), when compared to WT at 22 °C (Fig. 4C,D). Therefore, we did 
not see any UCP1 protein enhancement in the TLR4−/− mice after cold exposure. We observed a statistically sig-
nificance decrease in UCP1 expression in the TLR4−/− 6 °C group when compared to WT 6 °C group (Fig. 4C,D). 
Figure 4. TLR4 is required for cold-induced browning phenotype. (A) Representative image of WT and 
TLR4−/− mice were single-caged and housed at room temperature (23 °C) and cold exposure (6 °C) for six days 
(N = 3 per genotype and per condition). (B) Representative image of UCP1 staining in scAT across the different 
genotypes. (C) Depicted are representative immunoblots to detect phospho-HSL, total HSL, UCP1, ATGL 
and Adiponectin. N = 3 per group. (D) Densitometric evaluation of phospho-HSL, total HSL, UCP1, ATGL 
and Adiponectin levels. (E) qRT-PCR was performed to quantitate Citrate synthase, Me3 and Cpt1b mRNA in 
scAT from the different groups. N = 3 per group. Scale Bars, 25 μm and 100 μm. Graph shows the mean ± SEM. 
Statistical significance was determined by one-way ANOVA. *P < 0.05; **P < 0.01. ***P < 0.001.
www.nature.com/scientificreports/
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Although oxidative metabolism (TCA cycle) was stimulated by chronic cold exposure in both groups (WT and 
TLR4−/−), an increase in Cpt1b gene expression was evidenced only in the WT group, with no change in the 
TLR4−/− mice (Fig. 4E).
Atorvastatin treatment increases survival and attenuates browning. In order to propose 
a translational approach and to correlate the data with the genetic model, WT TB mice were treated with a 
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase enzyme inhibitor, atorvastatin (ATOR). In recent 
years15–17, the anti-inflammatory and pleiotropic effects of this drug have been described, such as inhibition of 
NFκB activation and downregulation of Tlr4 and Myd88 gene expression. We also confirmed the downregulation 
of Tlr4 after ATOR treatment in scAT, as illustrated in Fig. S3.
To evaluate if pharmacological attenuation of TLR4 would have an impact on the clinical features of cachexia, 
WT TB mice were treated with ATOR (Fig. 5). The treatment was effective in prolonging the mice survival 
(Fig. 5A) and also in attenuating scAT atrophy (2.0-fold) and tumor mass growth (49.7%) when compared to 
a TB untreated group (Fig. 5B). Other markers of the cachexia syndrome evolution in the animal model were 
attenuated in those treated with ATOR. Body weight (BW) plateau, which represents the highest value of body 
weight observed in the experimental period, showed an increase of 32% in the treated animal when compared 
to the WT TB group. The tumor of ATOR-treated animals appeared later than the tumor of the non-treated ani-
mals (Table S1). Lipolysis was also evaluated in 3T3-L1 cells. Cells that were stimulated with lipopolysaccharide 
(LPS) and treated with ATOR showed a reduced lipolytic response to the LPS stimulation when compared with 
untreated cells, showing a significant reduction at 6 hours (41.3%) and 24 hours (45.6%) as illustrated in Fig. 5C.
Interestingly, ATOR was also able to reduce cachexia-induced browning and atrophy of scAT (Fig. 5D,E). 
Furthermore, the profile of the signature browning genes from scAT showed marked downregulation of Ucp1 
(85.5%), Prdm16 (91.7%) and Cidec (98.3%) after ATOR treatment in TB mice, as shown in Fig. 5E. In respect 
of ATMφs polarization, we analyzed the classical markers for M1 (Nos2 and CD11c) and M2 (Arg1 and CD301) 
in the scAT. No significant difference was observed in mRNA for M1 markers (despite a strong trend). However, 
Arg1 expression increased 5.8-fold in the TB + ATOR mice. This suggests that ATOR treatment appeared to 
reverse the previously described M1 ATMφs polarization, a similar effect to that which we found in the TLR4−/− 
mice (Fig. 5F).
During cancer cachexia syndrome, systemic inflammation plays a key role in the scAT remodeling, directly 
influencing the composition of the immune system present in AT, and, consequently, the patient’s immune 
response. In the present study, we demonstrated that WT TB mice present high plasma concentrations of proin-
flammatory cytokines in response to cancer-associated cachexia (Fig. 5G). However, after pharmacological treat-
ment with ATOR, it was possible to see a significant decrease in almost all these cytokines, returning the plasma 
concentration levels to a degree comparable with the WT group (Control group - without cachexia). These results 
demonstrate that treatment with ATOR improved the inflammatory profile of the tumor-bearing mice and ame-
liorated some general cachexia parameters after ATOR treatment similarly to the values found in the TLR4−/− TB 
mice (Table S1).
Discussion
Cancer-associated cachexia is a complex metabolic state accompanied by poor quality of life, high mortality 
and also resistance to chemotherapy18–20. Several clinical interventions have sought to improve cachexia through 
anti-inflammatory drugs and insulin sensitizers but studies have shown limited results21,22. Circulating factors 
produced by the tumor and/or host itself may play an important role in therapeutic treatment for cachexia. Once 
the factors are identified, they can be targeted for therapeutic intervention.
During the development of cancer cachexia, AT remodeling occurs predominantly through morphofunc-
tional rearrangement that is an endpoint process associated with immune-metabolic dysfunction of such tis-
sue4,5,9,18,23. In WT TB mice, body weight loss and AT mass wasting were detected, as well as a set of features 
related to AT remodeling. Interestingly, the TLR4−/− TB animals were shown to be protected against the effects of 
cachexia, particularly in relation to an absence of weight loss and AT wasting. In obesity (in humans and in mice 
models)24–26 a close link between inflammation, over-production of extracellular matrix (ECM) components, the 
development of fibrosis and consequent tissue remodeling has been demonstrated in the liver and kidneys. In 
these organs, there is mounting evidence that TLR4 acts as a key regulator in fibrogenesis27–29, a condition that 
may or may not be related to TLR4−/− ATMφs response. However, the possible involvement of TLR4 and ECM 
remodeling in cancer cachexia was not a focus of this study and needs further analysis.
Another important aspect of cancer cachexia-induced AT remodeling is the establishment of AT inflamma-
tion that was recently shown to be characterized by increased recruitment of ATMφs, including activated M1 and 
M2 macrophages5. In fact, ATMφ infiltration of scAT has consistently been demonstrated in different experi-
mental models30. This scenario has also been demonstrated in patients with cancer and cachexia4,5. However, the 
polarization of ATMφs in scAT has only recently been addressed5,7. In this regard, we extended these findings by 
presenting in greater detail that in cachexia induced by LLC cells, ATMφs polarization tends to be directed to an 
M1 phenotype. On the other hand, the TLR4−/− TB mice presented a consistent attenuation in ATMφs infiltration 
in scAT, but in this phenotype, the polarization tended towards an M2 phenotype. The exact mechanism by which 
TLR4 deficiency affects AT inflammation remains to be explored and would require the generation of an adipose 
tissue-specific knockout mouse model for TLR4.
Regarding the morphological and inflammatory dysfunction that results in AT remodeling in response to 
cachexia, TG turnover is the most well-characterized metabolic disorder associated with this condition4,5,31, 
with increased lipolysis being the mechanism best described in the literature23,32. Higher adipocyte lipolysis was 
observed in the cachectic WT mice, which is in line with recent studies demonstrating that AT lipolysis repre-
sents a key factor involved in weight loss in cancer cachexia in both animals23,32 and human patients33. However, 
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Figure 5. Atorvastatin treatment increases survival and improved cachexia-remodeling in scAT. (A) Kaplan-
Meier survival curves show a statistically significant difference (P < 0.05) in survival between the Tumor 
Bearing (TB) mice (N = 15 per group) and Tumor Bearing + ATOR treatment (TB + ATOR) mice (N = 15 
per group). (B) Adipose tissue, muscle and tumor weights at study end. (C) Time course of lipolysis in 3T3-L1 
induced by LPS (100 ng) and LPS + ATOR treatment (100 μM). (D) Immunohistochemical analysis for UCP1 in 
scAT. (E) qRT-PCR was performed for Ucp1, Pgc1a, Prdm16, Cidea, Cidec, Adrb1 and  Adrb3 (F) Nos2, Cd11c, 
Cd301 and Arg1 (M1 and M2 macrophage polarization markers) for mRNA quantification in scAT from the 
different groups. N = 5 per group. (G) Heat map representing the circulating pro-inflammatory cytokines 
in the serum from the different experimental groups. White to brown scale depicts cytokine levels in pg/ml. 
Data were analyzed using the Bio-Plex manager software. N = 8 per group. Scale bars, 200 μm. Graph show 
the mean ± SEM. Significant differences were determined using Student’s t-test (B,E,F) and two-way ANOVA 
(C). Subcutaneous AT (scAT); Mesenteric AT (meAT); Brown AT (BAT); Extensor Digitorum Longus Muscle 
(EDL). *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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adipocytes from the TLR4−/− mice were less affected by cachexia and showed a very attenuated response to 
ISO-stimulation.
As TLR4−/− TB mice were found to be resistant to the lipolytic effects induced by cachexia, we also evaluated 
some parameters related to the cycle of NEFA release from the breakdown of stored TG and re-esterified to 
TG (TG turnover). In human patients with cachexia, enhanced TG turnover activity in AT has been shown, as 
determined by a metabolic labeling assay20. In our study, WT TB animals showed a reduction of palmitic acid 
level in the scAT, corroborating the other results regarding the increase in fatty acids associated with cachexia. 
Interestingly, this process showed less intensity in TLR4−/− TB mice, including in respect of AT morphofunc-
tional preservation. These data substantiate those found in some recent studies that demonstrated an impairment 
of TG turnover by cachexia5,32. However, it should be noted that the TLR4−/− animals already had lower levels of 
palmitic acid in the scAT compared to the WT animals. Thus, whether or not this fact is associated with metabolic 
repercussions requires further investigation.
In general, the effect of cachexia on expression of AT metabolic markers was attenuated in the absence of 
TLR4, particularly in genes related to glyceroneogenesis and TG reesterification. A study by Pang et al. proposed 
that TLR4 might play a role as a physiological regulator of fuel metabolism34. In their study, TLR4−/− mice showed 
lipid abnormalities during fasting that might result from increased TG mobilization, possibly through increased 
fatty acid reesterification in scAT, decreased fatty acid oxidation, and/or increased de novo lipogenesis in key 
metabolic tissues. These results corroborate those presented in this study, demonstrating that, in addition to 
reduced lipolysis, TLR4 deletion may also be involved the avoidance of the deleterious modifications in fatty acid 
reesterification, induced by cachexia.
It has recently been shown that cachexia induces AT browning in addition to changes in immune-modulatory 
activity. In this scenario, chronic inflammation and β-adrenergic activation of thermogenesis functionally coop-
erate in the pathogenesis of cachexia3,7. In the present study, LLC-induced cachexia resulted in a consistent 
browning phenotype (morphology) of scAT followed by a marked upregulation of Ucp1 levels. These results are 
in line with those presented in other studies with the same experimental model35.
Interestingly, TLR4−/− TB mice showed a significant reduction in AT browning, as well as in the levels of 
phosphorylation of p38 MAPK, both induced by cachexia. The browning phenotype induced by cancer cachexia 
might, therefore, be activated indirectly by p38 MAPK, and the presence of TLR4 appears to be important in 
this process. Recently, it was demonstrated that phosphorylation of p38 MAPK activity was higher in the UCP1 
positive axillary AT of cachectic (K5-SOS) animals7. Adaptive thermogenesis and UCP1 expression are mainly 
regulated by sympathetic tone through β-adrenergic signaling and cAMP levels, which can be directly sensed by 
protein kinase A (PKA) and thus lead to direct or indirect activation of p38 MAPK36,37. However, a well-designed 
recent study using experimental models demonstrated that full activation of adipose browning, including Ucp1 
expression, in mouse and human cachexia seems to be variable, and the functional contribution to overall energy 
coats needs to be determined23.
The reduction of browning induced by cachexia has been demonstrated in different studies, through treat-
ment with cyclooxygenase-2 inhibitor (Sulindac), β3-adrenergic receptor antagonist (SR59230A)7 and a knockout 
model for parathyroid hormone-related protein (PTHrP)38. However, none of these studies have shown results on 
survival, which is a key parameter to verify the pre-clinical efficacy of pharmacological intervention.
Taking into account the beneficial effects found in the genetic model (TLR4−/− TB), and to take a translational 
(preclinical) approach that would include evidence on survival, we chose to treat the animals with an already 
well-established drug with a well-characterized TLR4 antagonist effect (ATOR). Some elegant studies have con-
sistently shown that ATOR has an inhibitory effect on the TLR4 pathway15,39–43. Another important criterion for 
drug choice was its direct effect on the down-regulation of this receptor39–41 as well as regulation of downstream 
pathways15 and target cytokines42,43. Additionally, the fact that it is already well-established in the market, in addi-
tion to presenting a very favorable toxicity profile, was also considered44,45.
We demonstrated that ATOR treatment was effective in increasing the survival of the cachectic mice, in addi-
tion to attenuating the main signs of cachexia syndrome, an effect also observed in the genetic TLR4−/− model. In 
cachexia, systemic inflammation is highly dependent on the patient’s immune response46 and, at least in exper-
imental models, IL-6, TNF-α, and IL-1β are major contributors to the wasting syndrome6,47. The major inflam-
matory cytokines were abrogated in the same way, both in TLR4−/− and pharmacological inhibition of TLR4 in 
TB mice. In fact, systemic activation of TLR4 increases cytokine synthesis and release from various host cells as 
an innate immune response10. Moreover, a recent study showed the presence of elevated levels of TNF-α and 
IL-6 in animals bearing-LLC tumor, which was attenuated in TLR4−/− mice in the same experimental condition 
(cachexia)10, corroborating the findings of our study.
Moreover, in addition to the anti-inflammatory and protective effects of skeletal muscle mass previously 
demonstrated10, we have shown that TLR4 activation is “directly” involved in metabolic disorders in AT such 
as increased TG turnover and browning phenotype, both relevant parameters involved in the remodeling 
and dysfunction of AT induced by cachexia. We showed in the present study that TLR4 disruption attenuated 
AT remodeling and metabolic dysfunction during the syndrome, thus suggesting a possible therapeutic target for 
cancer-induced cachexia.
Some limitations of this study should be acknowledged. First, most of our findings are based on the data 
obtained from TLR4 whole-body knockout mice. Global TLR4 targeting extends our knowledge of the role of this 
receptor in AT remodeling caused by cancer cachexia. The TLR4 null mouse model has a significant advantage 
compared with other knockouts since it has prolonged survival from cachexia. The global knockout, however, 
did not allow us to track TLR4 function at specific developmental stages of cachexia. Second, although some 
well-designed studies have also demonstrated the direct effects of ATOR on modulating the various steps of the 
TLR4 signaling pathway, other classic drug effects, such as cholesterol-lowering or alternative anti-inflammatory 
may have beneficial effects related to the development of cachexia syndrome. Having additional orthogonal 
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approaches to modulate TLR4 signaling would be advantageous in validating our findings. However, statins have 
been reported to have some possible side effects including myopathy, which should be taken into account when 
considering their use in relation to the cachexia. Moreover, the exact mechanism of action of statins on Tlr4 
expression remains unknown. Although several papers show a downregulation in Tlr4 using statins, further stud-
ies are needed to explore the exact molecular mechanisms underlying the regulation of statin-dependent Tlr4 
downregulation. Therefore, from a comprehensive and translational point of view, the effectiveness of pharmaco-
logic inhibition of TLR4 by ATOR and other agents on the onset and progression of cancer cachexia, in particular 
the attenuation of the kinetics of tumor growth, still needs further study, especially in a clinical setting.
Conclusion
Our combined data from the TLR4 knockout model and ATOR treatment clearly shows that TLR4 plays an essential 
role in mediating tumor-induced AT remodeling and cachexia development. Therefore, disturbing TLR4 signaling 
systemically may prevent scAT remodeling by abrogating, at least in part, its indirect effects. At this point, both the 
genetic ablation and the pharmacological inhibition of TLR4 were able to attenuate both the remodeling of the AT 
(atrophy and inflammation) and the metabolic dysfunction (lipolysis) induced by cachexia (Fig. 6). Also, for the 
first time, we have presented evidence that the TLR4 receptor may play an essential role in the browning phenotype 
induced by cachexia. Interestingly, TLR4−/− also showed resistance to browning, suggesting that the TLR4 receptor 
plays an essential role in the morphological alterations and homeostatic energy expenditure. Finally, it is clinically 
noteworthy that animals treated with a TLR4 inhibitor displayed general attenuation of AT remodeling and systemic 
inflammation (Fig. 6), presenting an increase in the mice survival, which may have a relevant role as an adjuvant 
treatment option, as well as being a strong candidate for novel anti-cachectic therapy development.
Methods
Animal Model. Eight-week-old male C57BL/6 J and TLR4−/− (Toll-like Receptor 4 - B6.B10ScN-Tlr4lps-del/
JthJ - JAX stock #007227) mice were obtained from Jackson Laboratory, for validation and phenotypic character-
ization of TLR4−/− see Fig. S4. Mice were housed on a 12 h light/dark schedule and had free access to water and 
food. Mice were divided into four different groups: Wild Type (WT); WT tumor-bearing (WT TB); TLR4−/− and 
Figure 6. The working model that TLR4 disruption ameliorates adipose tissue remodeling during cancer 
cachexia syndrome. Cancer-induced cachexia is characterized by systemic inflammation, body weight 
loss and AT remodeling. We show that TLR4 disruption (knockout model of TLR4 and pharmacological 
inhibition by ATOR treatment) ameliorates AT remodeling, in particular, preservation of adipocyte atrophy 
and attenuation of browning phenotype in scAT, as well as inflammatory responses during cancer cachexia 
syndrome. Additionally, TLR4 disruption was effective in prolonging the survival and reducing tumor mass 
growth. Therefore, these data suggest that TLR4 plays an important role during cachexia development. Here, 
we suggested a new potential therapeutic target for cancer cachexia syndrome. Parts of the figure were drawn 
using images from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons 
Attribution 3.0 Unported License (https://smart.servier.com/).
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TLR4−/− tumor-bearing (TLR4−/− TB). For chronic cold challenge, WT and TLR4−/− mice were single-caged and 
housed at room temperature (23 °C) and cold exposure (6 °C) for six days (n = 5 per genotype and per condition) 
on a 12 h light/12 h dark cycle with access to a standard chow diet. All of the studies performed were approved 
by the Ethical Committee for Animal Research from the University of Mogi das Cruzes approved all the adopted 
procedures, which were carried out in accordance with the ethical principles stated by the Brazilian College of 
Animal Experimentation - Protocol n. 009/2013.
Tumor Model and Collection of Tissues. Lewis Lung Carcinoma (LLC) tumor cells were used for 
inducing cancer cachexia syndrome. LLC was injected subcutaneously into the right flanks (200 μl LLC cells 
−3.5 × 105). Non-tumor bearing control mice received Phosphate-buffered saline (PBS) only. Development of 
cachexia was monitored by tumor size and body weight for 28 days. The impact of tumor growth and develop-
ment of cachexia on animal welfare were considered, with appropriate measures to monitor and alleviate suffering 
implementation according to adopted endpoint criteria9,48. Overnight-fasted mice were euthanized by decapi-
tation without anesthesia, serum was collect and centrifuged (400 g, 15 min, 4 °C) and stored at −80 °C for later 
analysis. After euthanasia, subcutaneous adipose tissue (scAT) was carefully dissected and weighed. All the mice 
were checked if they are positive for the presence of metastasis in the lungs, as well as other visceral organs. If 
there is a presence of metastasis, the animals are excluded from the experimental group (exclusion criteria). Body 
weight was measured daily, at the same time, over the 28-day experimental period on a precision scale (Ohaus®).
Atorvastatin Treatment. For the inhibition of the TLR4 receptor via pharmacological action, Atorvastatin 
(Citalacor®) treatment was performed, currently described as a selective antagonist for TLR4. Only WT TB mice 
were used for this procedure. The animals were divided into two experimental groups: WT TB + PBS and WT 
TB + Atorvastatin (TB + ATOR). The animals that received Atorvastatin were treated with a concentration of 
10 mg/kg/day by orogastric gavage during the 27-day of protocol. The same protocol was performed for the ani-
mals that underwent the survival experiment.
Histological analysis. scAT was fixed in HistoChoice® MB (Amresco), pH 7.4 for 3 h. Fixed tissues were 
dehydrated and 8-μm sections were used. H&E and Picrosirius staining were performed according to stand-
ard procedures (Sigma-Aldrich). The sections were analyzed with a Leica microscope (DM 750). Morphometric 
aspects were measured by Imagen Pro-Plus 6.0.
Immunohistochemistry. Immunohistochemistry of scAT was carried out with sections fixed by 
HistoChoice® MB (Amresco) at pH 7.4 for 3 hours. Fixed tissues were dehydrated and 5-μm sections were used. 
Dehydrated tissue was blocked using a two different blocking buffers, a buffer solution of endogenous peroxi-
dase activity with 0.3% H2O2 in methanol and buffer solution of free protein binding sites with 5% normal goat 
serum. The following primary antibodies were used: UCP1 (ab10983), TNFα (ab6671), CD68 (ab955) and CD3 
(ab16669). We employed the polymer-peroxidase method, using Histofine Simple Stain MAX-PO (Nichirei 
Biosciences) and Sigma Fast 3,3-diaminobenzidine as substrate (Sigma-Aldrich). Sections were counter-stained 
with hematoxylin.
RNA isolation and qRT-PCR. Total RNA was isolated from scAT using QIAzol Lysis Reagent Protocol 
(QIAGEN) following the manufacturer’s instructions. cDNA was synthesized from 2 μg of total RNA using 
iScript cDNA Synthesis Kit (BioRad). RPL19 served as control for internal reference gene. Primer sequences used 
for qRT-PCR analyses were listed in Table S2. Analyses of qRT-PCR products were performed with the Prism 
7500 SDS software (Thermo Fisher Scientific). Relative quantification of mRNA amount was obtained by the by 
2−(ΔΔCt) method.
Western Blot. For protein expression analyses, tissues were homogenized in lysis buffer (20 mM HEPES, 
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 10% glycerol, 0.5% sodium deoxycholate) supple-
mented with Halt protease and phosphatase inhibitors (Thermo Pierce). Samples from tissue lysates were then 
resolved by SDS-PAGE, and immunoblots were performed using standard protocols. Membranes were blotted 
with the following antibodies: HSL (ab45422); phospho-HSL Ser660 (Cell Sig. #4126); ATGL (Cell Sig. #2138); 
P38 MAPK (Cell Sig. #8690); phospho P38 MAPK (Cell Sig. #9211); phospho-AMPK (Thr172 - Cell Sig. 2531); 
AMPK (Cell Sig. 2532); phospho-PKA substrate (Cell Sig. #9624); Adiponectin (ab62551) and UCP1 (ab10983), 
all overnight. The membranes were incubated with the goat anti-rabbit IgG conjugated to horseradish peroxidase 
secondary antibody (7074 - Cell Signaling Technology) for 1 h at room temperature and were detected by ECL 
Prime (Amersham). For the control of protein loading and transfer, we used Ponceau staining of the membranes. 
Quantification of the antigen–antibody complex was performed by the ImageJ Analysis Software.
SVF isolation and Flow cytometry analysis. Stroma vascular fraction (SVF) from scAT were excised 
and minced in PBS with calcium chloride and 0.5% BSA. Collagenase II (Sigma-Aldrich) was added to 1 mg/ml 
and incubated at 37 °C for 30 minutes with shaking. The cell suspension was filtered through a 100 μm filter 
and then spin down at 300 g for 5 minutes to separate floating adipocytes from the SVF pellet. Cells were incu-
bated with Fc Block (BD Biosciences) prior to staining with conjugated antibodies for 15 minutes at 4 °C. SVF 
were purified and stained with the following antibody panel: ATMφs were defined as CD68+F4/80+ subpopula-
tions. M1 and M2 ATMφs were defined as CD68+F4/80+CD11c+CD206− and CD68+F4/80+CD11c−CD206+, 
respectively. Cells were analyzed using a BD Accuri (BD biosciences). The data was analysis was performed using 
FlowJo.
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Measurement of plasma cytokines. Plasma was collected using plasma separators (BD Biosciences). 
Cytokine levels were determined using a Milliplex assay kit (Milliplex MAP mouse cytokine/chemokine magnetic 
bead panel, #MCYTOMAG-70K - Millipore). Data were analyzed using the Bio-Plex manager software (Bio-Rad 
Laboratories).
Lipolysis assay. Isolated adipocytes were suspended in 40 ml of Kreb’s/Ringer/phosphate buffer (pH 7.4, 
with 1% BSA) in 0.6 ml microtubes with 20 ml of adenosine deaminase (0.2 U/ml) and were incubated at 37 °C 
for 5 min to degrade endogenously released adenosine, which is a potent inhibitor of lipolysis. The cells were 
then incubated for 1 h at 37 °C either in the presence (stimulated) or absence (basal) of isoproterenol (10−5M, 
β-adrenergic agonist) in a final volume of 200 μL. At the end of incubation, the reaction mixture was blocked by 
moving the tubes to a cold-water bath followed by centrifugation at 3500 g for 5 min at 4 °C. The infranatant was 
carefully transferred to microtubes containing 150 μL of silicone oil and re-centrifuged at 3500 g for 2 min. The 
concentration in the medium of released glycerol (nmol/104 cells) was quantified with a commercially availa-
ble reagent (Sigma-Aldrich), measured according to the manufacturer’s instructions. The lipolysis response was 
assessed by the ratio of glycerol released relative to the basal condition. For additional analyses of the possible 
effect of ATOR on inhibiting lipolysis, 3T3-L1 cells were stimulated during 1 h, 6 h and 24 h with lipopolysaccha-
ride (LPS, 100 ng/mL). The concentration in the medium of released glycerol was quantified with a commercially 
available reagent (Sigma-Aldrich), measured according to the manufacturer’s instructions.
Cell culture. 3T3-L1 pre-adipocytes were plated at 1 × 104 in 24-well culture plates and cultured in DMEM 
(Dulbecco’s Modified Eagle’s Medium) with 4500 mg glucose supplemented with 10% bovine serum and 2% pen-
icillin with streptomycin at pH 7.4. The cells were maintained at 37 °C with 5% carbon dioxide (CO2) so as not 
to reach complete confluence until they were induced to differentiate. Preadipocytes were brought to complete 
confluence (day-2) and after two days of confluence, the culture medium was replaced by differentiation inducer 
medium, consisting of DMEM, supplemented with 10% fetal bovine serum (FBS), 1 μM dexamethasone, 0.5 mM 
3-isobutyl-1-methylxanthine (IBMX) and 1.67 μM bovine insulin. From the second day of differentiation, the 
cells were maintained in culture medium containing only 0.83 μM insulin and 10% FBS which was changed every 
48 hours for eight days.
Adipose Tissue lipid analysis. The total scAT lipids were extracted using the method of Folch49. 
Transesterification of the lipid extracts was performed with acetyl chloride (5% CH3COCl in methanol) and fatty 
acids (FAs) composition was determined as methyl esters using a Varian Model 3900 Gas Chromatograph (GC) 
coupled to flame ionization detection (FID). FAs were identified by comparing the retention time using three 
known standards of fatty acid methyl esters (FAME). The FAMEs were analyzed in a capillary column (CP Wax 52 
CB), 0.25 mm in thickness, 0.25-μm inside diameter, and 30 m in length. Hydrogen was used as a carrier gas at a 
linear velocity of 22 cm/s. The temperature program was 170 °C for 1 min followed by a 2.5 °C/min ramp to 240 °C, 
and a final hold time of 5 min. Injector and FID temperatures were 250 and 260 °C, respectively. The profiles of 
individual FAs were calculated using an automatic integrator and presented as percentages of total FAs according 
to the peak areas. Data are presented as palmitic acid profile (%) of total lipids.
Non-Esterified Fatty Acids (NEFA). 50 μL of serum was collected from the different groups and the levels 
of NEFA was quantified using a kit following the manufacturer’s recommendations (MAK044, Sigma).
Statistical analysis. Data were analyzed in GraphPad Prism 7 (GraphPad Software). The statistical signif-
icance of the differences in the means of experimental groups was determined by Student’s t-test or and 2-way 
ANOVA, followed by Tukey’s post hoc comparison tests. The data are presented as means ± SEM. P values ≤ 0.05 
were considered significant.
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